Dr. Ramesh Kumar, MD
Rheumatology (Rheumatology Physician)
3 Plaza Drive Suite 16
Toms River, NJ 08757
Who else practices at this address →
Ocean County includes primary care (21% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 733
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
NJ license MA 071228
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ocean Medical Center Brick, NJ
- Community Medical Center Toms River, NJ
- Southern Ocean Medical Center Manahawkin, NJ
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 733
- Services billed
- 25,969
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 1,694 | 550 |
| Injection, denosumab, 1 mg | 318 | 14 |
| Injection, methylprednisolone acetate, 40 mg | 249 | 126 |
| New patient office or other outpatient visit, 45-59 minutes | 248 | 248 |
| Insertion of needle into vein for collection of blood sample | 238 | 151 |
| Injection, zoledronic acid, 1 mg | 197 | 41 |
| Injection of additional new drug or substance into vein | 175 | 56 |
| Injection of trigger points, 1-2 muscles | 169 | 76 |
| Infusion, normal saline solution, 250 cc | 145 | 45 |
| Administration of chemotherapy into vein, each additional hour | 128 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methylprednisolone Other prescribers in Toms River, NJ | 1,429 |
| Methotrexate (methotrexate sodium) Other prescribers in Toms River, NJ | 516 |
| Prednisone Other prescribers in Toms River, NJ | 457 |
| Hydroxychloroquine Sulfate Other prescribers in Toms River, NJ | 399 |
| Meloxicam Other prescribers in Toms River, NJ | 150 |
| Cyclobenzaprine Hcl Other prescribers in Toms River, NJ | 118 |
| Folic Acid Other prescribers in Toms River, NJ | 98 |
| Allopurinol Other prescribers in Toms River, NJ | 92 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Toms River, NJ | 91 |
| Enbrel Sureclick (etanercept) Other prescribers in Toms River, NJ | 86 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 77 payments worth $939 in total to this clinician.
| AbbVie Inc. | $577 |
|---|---|
| Janssen Biotech, Inc. | $248 |
| Amgen Inc. | $84.67 |
| Almatica Pharma LLC | $15.57 |
| E.r. Squibb & Sons, L.l.c. | $13.65 |
| Food and Beverage | $787 |
|---|---|
| Education | $152 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jul 31, 2025 | Education TREMFYA · Immunology · in-kind | $76.99 |
| Janssen Biotech, Inc. Mar 18, 2025 | Education TREMFYA · Immunology · in-kind | $74.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $6,935 in research payments for these studies, mostly to the institutions running them.
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc. · Active, not recruiting · NCT02629159 - M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc. - A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
AbbVie Inc. · Completed · NCT03086343
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.